Aortic Valve Stenosis Clinical Trial
— PLANETOfficial title:
Pacing of the Left Bundle Branch Area NEcessitated After TAVR
Verified date | January 2023 |
Source | Ludwig-Maximilians - University of Munich |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Prospective, randomized, single center clinical trial to compare the outcome of left bundle branch area pacing versus right ventricular apical pacing in patients with higher degree atrio-ventricular block and a normal left ventricular function after transcatheter aortic valve replacement.
Status | Active, not recruiting |
Enrollment | 30 |
Est. completion date | April 2025 |
Est. primary completion date | April 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Successful TAVR implantation for classical (high flow high gradient), symptomatic aortic valve stenosis - LVEF =50% - Guideline-based indication for pacing due to AV block III°, AV block II°, or symptomatic bradycardic atrial fibrillation with an expecteed ventricular pacing burden >20% - Signed informeed conseent to study participation Exclusion Criteria: - LVEF <50% - Expected pacing burden <20% - Pre-existing implanted cardiac device - Participation in a concurring interventional trial - age <18 years - Current preegnancy - life expectancy <6 months |
Country | Name | City | State |
---|---|---|---|
Germany | LMU Klinikum | Munich | BY |
Lead Sponsor | Collaborator |
---|---|
Ludwig-Maximilians - University of Munich |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Pacemaker-associated complications | 3 months | ||
Other | Pacemaker-associated complications | 12 months | ||
Other | Pacemaker-associated complications | 24 months | ||
Other | procedural implantation success | dichotomous yes / no | basline | |
Other | Implantation procedure duration | baseline | ||
Other | Fluoroscopy duration | baseline | ||
Other | Fluoroscopy dose | baseline | ||
Primary | QRS duration | QRS duration on 12-lead ECG, defined as earliest Q to latest S across all leads | 3 months | |
Secondary | QRS duration | QRS duration on 12-lead ECG, defined as earliest Q to latest S across all leads | 12 months | |
Secondary | QRS duration | QRS duration on 12-lead ECG, defined as earliest Q to latest S across all leads | 24 months | |
Secondary | Death of any cause | 3 months | ||
Secondary | Death of any cause | 12 months | ||
Secondary | Death of any cause | 24 months | ||
Secondary | Death of cardio-vascular cause | 3 months | ||
Secondary | Death of cardio-vascular cause | 12 months | ||
Secondary | Death of cardio-vascular cause | 24 months | ||
Secondary | Re-hospitalization due to heart failure | 3 months | ||
Secondary | Re-hospitalization due to heart failure | 12 months | ||
Secondary | Re-hospitalization due to heart failure | 24 months | ||
Secondary | Change in left ventricular ejection fraction | 3 months | ||
Secondary | Change in left ventricular ejection fraction | 12 months | ||
Secondary | Change in left ventricular ejection fraction | 24 months | ||
Secondary | Change in echocardiographic left ventricular enddiastolic diameter | 3 months | ||
Secondary | Change in echocardiographic left ventricular enddiastolic diameter | 12 months | ||
Secondary | Change in echocardiographic left ventricular enddiastolic diameter | 24 months | ||
Secondary | Echocardiographic assessment of degreee of atrio-ventricular valve insufficiency | 3 months | ||
Secondary | Echocardiographic assessment of degreee of atrio-ventricular valve insufficiency | 12 months | ||
Secondary | Echocardiographic assessment of degreee of atrio-ventricular valve insufficiency | 24 months | ||
Secondary | Echocardiographic assessment of right ventricular ejection fraction | 3 months | ||
Secondary | Echocardiographic assessment of right ventricular ejection fraction | 12 months | ||
Secondary | Echocardiographic assessment of right ventricular ejection fraction | 24 months | ||
Secondary | Change in New York heart failure classification status | 3 months | ||
Secondary | Change in New York heart failure classification status | 12 months | ||
Secondary | Change in New York heart failure classification status | 24 months | ||
Secondary | Change in laboratory biomarkers NT-proBNP | 3 months | ||
Secondary | Change in laboratory biomarkers NT-proBNP | 12 months | ||
Secondary | Change in laboratory biomarkers NT-proBNP | 24 months | ||
Secondary | Change in functional status by 6 minute walk | 3 months | ||
Secondary | Change in functional status by 6 minute walk | 12 months | ||
Secondary | Change in functional status by 6 minute walk | 24 months | ||
Secondary | Change in EQ-5D quality of life | 3 months | ||
Secondary | Change in EQ-5D quality of life | 12 months | ||
Secondary | Change in EQ-5D quality of life | 24 months | ||
Secondary | Occurence of arrhythmias | 3 months | ||
Secondary | Occurence of arrhythmias | 12 months | ||
Secondary | Occurence of arrhythmias | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03186339 -
Validation of the "TASQ" in Patients Undergoing SAVR or TF-TAVI
|
||
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Terminated |
NCT02854319 -
REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System
|
N/A | |
Recruiting |
NCT05601453 -
The ReTAVI Prospective Observational Registry
|
||
Withdrawn |
NCT05481814 -
CPX in Paradoxical Low Flow Aortic Stenosis
|
||
Completed |
NCT02241109 -
Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity
|
N/A | |
Completed |
NCT01700439 -
Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve
|
N/A | |
Recruiting |
NCT04429035 -
SLOW-Slower Progress of caLcificatiOn With Vitamin K2
|
N/A | |
Completed |
NCT04103931 -
Impact of a Patient Decision Aid for Treatment of Aortic Stenosis
|
N/A | |
Completed |
NCT03950440 -
Assessing the Incidence of Postoperative Delirium Following Aortic Valve Replacement
|
||
Active, not recruiting |
NCT02661451 -
Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)
|
N/A | |
Completed |
NCT02847546 -
Evaluation of the BARD® True™ Flow Valvuloplasty Perfusion Catheter for Aortic Valve Dilatation
|
N/A | |
Completed |
NCT02792452 -
Clinical Value of Stress Echocardiography in Moderate Aortic Stenosis
|
||
Completed |
NCT02758964 -
Evaluation of Cerebral Thrombembolism After TAVR
|
||
Not yet recruiting |
NCT02541877 -
Sizing-sTrategy of Bicuspid AoRtic Valve Stenosis With Transcatheter Self-expandable Valve
|
Phase 3 | |
Not yet recruiting |
NCT02536703 -
Safety and Efficacy of Lotus Valve For TAVI In Patients With Severe Aortic Stenosis In Chinese Population
|
Phase 3 | |
Completed |
NCT02249000 -
BIOVALVE - I / II Clincial Investigation
|
N/A | |
Not yet recruiting |
NCT02221921 -
Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI
|
N/A | |
Active, not recruiting |
NCT02080299 -
Protection by Remote Ischemic Preconditioning During Transcatheter Aortic Valve Implantation
|
Phase 2 | |
Terminated |
NCT01939678 -
Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease
|